The neurotensin receptor (NTS1) has emerged as an interesting target for molecular imaging and radiotherapy of NTS-positive tumors due to the overexpression in a range of tumors. The aim of this study was to develop a 177 Lu-labeled NTS1 radioligand, its application for radiotherapy in a preclinical model and the imaging of therapy success by small-animal positron emission tomography (µPET) using [ 
Introduction
Neurotensin (NT) is a peptide consisting of 13 amino acids (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-ArgArg-Pro-Try-Ile-Leu) that has been originally isolated in 1973 by Carraway and Leeman from calf hypothalamus [1] . The biologically active sequence is the C-terminal part NT(8-13) (Arg-Arg-ProTyr-Ile-Leu) [2] which binds to the three neurotensin receptor subtypes NTS1, NTS2, NTS3 [3] and has therefore been selected as a lead structure for medicinal chemists [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . The NTS1 is upregulated in various tumor types including prostate, pancreas, mamma, lung and colon carcinoma [14] [15] [16] . In addition, NTS1 shows negligible expression in healthy tissues where these tumors arise from, making it a very specific molecular target for imaging and targeted cancer therapy [16] . NT (8) (9) (10) (11) (12) (13) is rapidly degraded by endogenous peptidases in vivo, therefore a variety of studies addressed this issue by modifying the amino acid sequence of NT (8) (9) (10) (11) (12) (13) [17] [18] [19] [20] [21] [22] [23] .
Up to now, only a few NT (8) (9) (10) (11) (12) (13) analogs have been radiolabeled with an isotope suitable for endoradiotherapy [24] [25] [26] [27] . Among these rare examples, the 188 Re-labeled peptide -NT-XIX‖ with the amino acid sequence (N α His)Ac-Arg-(N-CH 3 )-Arg-Pro-Dmt-Tle-Leu has been used for radiotherapy studies on tumor-bearing nude mice [24] . This radiopeptide showed promising effects, as the tumor growth in the animals was decreased at day 6 after begin of treatment. However, this study did not use successive diagnostic imaging experiments, such as positron emission tomography (PET) imaging, in a longitudinal setup for the prediction of therapy outcome. Lutetium-177 is a -emitter with a maximum energy of 0.5 MeV and a half-life of 6.7 days, displaying favorable physical properties compared to rhenium-188 (E max = 2.1 MeV, t ½ = 17 h). Lutetium-177 has a maximal tissue penetration of 2 mm, making it an optimal radionuclide for the irradiation of small tumors. Therefore, we aimed at developing a 177 Lu-labeled NT-derivative, based on our previously reported metabolically stable amino acid sequence NLys-Lys-Pro-Tyr-Tle-Leu [28, 29] , and studied the applicability of this radiopeptide ([ 177 Lu]NT127, Figure 1 ) for endoradiotherapy in NTS1-positive HT29-tumor-bearing nude mice.
The various integrin-specific PET tracers, all derived from pentacyclic RGD peptides [30, 31] , should be excellent molecular tools for monitoring early response of tumors to (radio)therapy, since antiangiogenic effects should occur at early stages after successful treatment [32] [33] [34] . Consequently, we studied the suitability of [ 68 Ga]DOTA-RGD ( Figure 1 , [35] ) for the noninvasive monitoring of tumor response to radiotherapy with [ 177 Lu]NT127 in a pilot study by successive PET imaging experiments, including days 7, 14, 21 and 28 after treatment and varying the administration of the dose from four fractionated doses (4 × 11-14 MBq, n = 4 mice) to a single high dose (1 × 50 MBq, n = 3 mice). 
Experimental

General
Reagents, building blocks and dry solvents were obtained from commercial sources and were used as received. Analytical radio-HPLC was performed on an Agilent 1100 system (Agilent Technologies, Böblingen, Germany) equipped with a quaternary pump and variable wavelength detector and radio-HPLC detector D505TR (Canberra Packard, Schwadorf, Austria). Computer analysis of the HPLC data was performed using FLO-One software (Canberra Packard).
Synthesis of NT127
Unless otherwise noted, reactions were conducted without inert atmosphere. Microwave assisted (Discover ® microwave oven, CEM Corp., Kamp-Lintfort, Germany) peptide synthesis was carried out in glass tubes loosely sealed with a silicon septum. Remark: the development of overpressure was avoided by using DMF as the solvent. In between each irradiation step, intermittent cooling of the reaction mixture to a temperature of −10 °C was achieved by sufficient agitation in an ethanol-ice bath. Preparative RP-HPLC was performed using Agilent 1100 preparative series (column: Zorbax Eclipse XDB-C8, 21.2 × 150 mm, 5 µm particles [C8], flow rate. 10 mL /min, detection wavelength: 220 nm) and solvent systems as specified below. Purity and identity were assessed by analytical RP-HPLC (Agilent 1100 analytical series, column: Zorbax Eclipse XDB-C8 analytical column, 4.6 × 150 mm, 5 µm, flow rate: 0.5 mL/min, detection wavelength: 220 nm) coupled to a Bruker Esquire 2000 mass detector equipped with an ESI-trap. Solvent systems are specified below. The peptide synthesis was achieved starting from commercially available Fmoc-Leu-Wang resin (Novabiochem ® , Merck KGaA, Darmstadt, Germany, loading 0.64 mmol/g). Amino acids were incorporated as their commercially available derivatives in the following order: Fmoc-Tle-OH (a), Fmoc-Tyr(tBu)-OH (b), Fmoc-Pro-OH (c), Fmoc-Lys(Boc)-OH (d), N-Fmoc-N-(4-Boc-aminobutyl)-Gly-OH (e, Aldrich, Taufkirchen, Germany), Boc-Lys(Fmoc)-OH (f), Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid (g, Novabiochem) and 4,7,10-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid (DOTA-tri-t-Bu-ester, h, Chematech, Dijon, France). Elongation of the peptide chain was done by repetitive cycles of Fmoc deprotection applying 20% piperidine in DMF (microwave irradiation: 5× 5 s, 100 W), followed by 5 washings with DMF and subsequent peptide couplings using the following conditions: AA/PyBOP/diisopropylethylamine HOBt (5 eq/5 eq/5 eq/7.5 eq for a,b,c,d and 4 eq/4 eq/4 eq/6 eq for g) or AA/HATU/DIPEA (4 eq/4 eq/4 eq for e, 5 eq/5 eq/5 eq for f performing the coupling twice and 2.6 eq/2.6 eq/2.6 eq for h). The building blocks and reagents were dissolved in a minimum amount of DMF and the irradiation was performed 15× 10 s employing 50 W. After the last acylation step, the resin was 10× rinsed with CH 2 Cl 2 and dried in vacuo. The on resin cleavage of t-Bu and Boc groups was achieved by stirring in a mixture of 10% v/v conc. H 2 SO 4 in dioxane at 8 °C for 2 h and subsequent washing with 30% v/v DIPEA in CH 2 Cl 2 , followed by CH 2 Cl 2 (2×). The cleavage from the resin was performed using a mixture of TFA/phenol/H 2 O/triisopropylsilane 88:5:5:2 for 2 h. After evaporation of the solvent and precipitation in tert-butylmethyl ether, the crude peptide was purified using preparative RP-HPLC (eluent: CH 3 CN (A) + 0.1% HCO 2 H in H 2 O (B) applying a linear gradient 3%-20% A in 97%-80% B in 16 min, t R : 13.9 min) and subsequent lyophilization to afford the peptide as the formate salt. Peptide purity and identity was assessed by analytical HPLC. System 1:10%-40% CH 3 
Neurotensin Receptor Binding Experiments
Receptor binding data were determined according to protocols as described previously [6, 36] . In detail, NTS1 binding was measured using homogenates of membranes from CHO cells stably expressing human NTS1 at a final concentration of 2 μg/well and the radioligand [ Protein concentration was generally determined by the method of Lowry using bovine serum albumin as standard [37] . Data analysis of the competition curves from the radioligand binding experiments was accomplished by non-linear regression analysis using the algorithms in PRISM5.0 (GraphPad Software, San Diego, CA, USA). EC 50 values derived from the resulting dose response curves were transformed into the corresponding K i values according to the equation of Cheng and Prusoff [38] .
Synthesis of [ 177 Lu]NT127
NT127 ( The radiochemical yield and radiochemical purity was determined from an aliquot taken from the reaction mixture by radio-HPLC (t R = 2.20 min; Chromolith RP-18e, 10 × 4.6 mm, 10%-50% acetonitrile (0.1% TFA) in water (0.1% TFA) in a linear gradient over 5 min, 4 mL/min) and was determined >98%.
Synthesis of [ 68 Ga]DOTA-RGD
To the DOTA-conjugated precursor c(RGDfK(DOTA)) [35] (10 nmol) in acetate buffer (2.5 M, 140 µL) was added an aliquot of [
68 Ga]GaCl 3 (200 MBq in 500 µL, 0.6 M HCl), freshly eluted from a 68 Ge/ 68 Ga generator (IDB Holland BV (Baarle-Nassau, The Netherlands)/iThemba LABS (Cape Town, South Africa)), resulting in a final pH of 4.0. After incubation for 10 min at 98°C, the solution was neutralized by the addition of sodium bicarbonate (1 M, 120 µL). The radiochemical yield was >98% as determined by radio-HPLC (t R = 1.30 min; Chromolith RP-18e, 10 × 4.6 mm, 10%-50% acetonitrile (0.1% TFA) in water (0.1% TFA) in a linear gradient over 5 min, 4 mL/min) and the specific activity was determined to be 10-15 GBq/µmol. The resulting solution was used for small animal PET studies without further purification.
Stability of [ 177 Lu]NT127
An aliquot of [ 177 Lu]NT127 (30 µL, about 2 MBq) was added to human serum (200 µL) and incubated at 37 °C. Aliquots (25 µL) were taken at various time intervals (5-210 min) and quenched in ethanol/water (1:1, 100 µL). The samples were centrifuged, and the supernatants were analyzed by radio-HPLC (t R = 2.20 min; Chromolith RP-18e, 10 × 4.6 mm, 10%-50% acetonitrile (0.1% TFA) in water (0.1% TFA) in a linear gradient over 5 min, 4 mL/min).
Cell Culture
The human NTS1-expressing cell line HT29 (ECACC NO 91072201) [39] , was grown in culture medium (McCoy's 5a medium containing glutamine (2 mM) supplemented with fetal bovine serum (FBS, 10%)) at 37 °C in a humidified atmosphere of 5% CO 2 . Cells were routinely subcultured every 3-4 days. Viability of the cells was determined by staining with trypan blue and was >90% for all cells used in in vitro and in vivo studies.
Internalization and Efflux Studies with [ 177 Lu]NT127
Three days before experimental use, approximately 250,000 HT29 cells were seeded in 24-multiwell plates. The medium was changed to binding buffer (culture medium supplemented with 1% bovine serum albumin (BSA), HEPES (10 mM), chymostatin (2 mg/L) and soybean trypsin inhibitor (100 mg/L), 0. as described above. After an incubation time of 30 min at 37 °C the plates were placed on ice and the cells were washed with ice-cold PBS (500 µL), acidic wash buffer (500 µL, 1 min) and again with ice-cold PBS (500 µL). Subsequently, fresh binding buffer (500 µL) was added to each well and the plates were incubated at 37 °C. After 5 min, 15 min, 30 min, 45 min, 60 min and 90 min the plates were placed on ice, the supernatant was transferred to a counting tube, the cells were washed once with ice-cold PBS (500 µL) and this washing PBS was combined with the respective supernatant in the counting tubes. Cells were harvested with NaOH (0.1 M, 1 mL) and cell suspensions and washing solutions were counted in a gamma counter (Wizard Wallac). The experiment was performed twice in quadruplicate.
Animal Model (Nude Mice Bearing HT29 Xenografts)
All animal experiments were performed in compliance with the protocols approved by the local animal protection authorities (Regierung Mittelfranken, Ansbach, Germany, No. 54-2532.1-22/10). Female athymic nude mice (nu/nu) were obtained from Harlan Winkelmann GmbH (Borchen, Germany) at 4 weeks of age and were kept under standard conditions (12 h light/dark) with food and water available ad libitum. HT29 cells were harvested and suspended in sterile PBS at a concentration of 10 7 cells/mL. Each mouse was injected subcutaneously in the lower region of the left shoulder on the back with viable cells (2 × 10 6 ) in PBS (200 μL). These mice were sacrificed by cervical dislocation at 4 h post injection (p.i.) and organs and tissue were removed, weighed and counted as described above. . Each dose contained between 0.3-0.7 nmol NT127. The body weight of the mice was determined three times a week and the diameter of the tumors was measured with a calliper three times a week for 30-33 days starting the day of the first injection (day 0). An additional group of three animals was injected with a single low dose of 21 MBq/mouse. These were also used for histological staining of tissue samples from kidney and liver.
Biodistribution Studies
Radiotherapy Studies with [
PET scans and image analysis were performed using a microPET rodent model scanner (Inveon, Siemens Healthcare, Erlangen, Germany under isoflurane anesthesia (4%). Animals were subjected to a 15 min scan starting from 45 min p.i. After 3D-OSEM iterative image reconstruction with decay and attenuation correction, regions of interest (ROIs) were drawn over the tumor region, and the mean within a tumor was converted to standard uptake values (SUV) considering the injected activity and body weight.
Histology of Tissue Samples from Kidney and Liver
28 days after first treatment the mice were sacrificed by cervical dislocation and kidneys and liver were dissected and immediately fixed in 4% neutral buffered formalin at room temperature overnight and then stored in phosphate buffered saline at 4 °C. For histological examinations the tissue was paraffin-embedded, cut in four-micrometer sections and stained with Masson-Goldner trichrome.
Quantification of tissue inflammation was done using a digital light microscope (Axioplan 2 imaging, Zeiss) with the software Metafer 4 (v. 3.9.1) and VSlide (v. 1.0.125). A virtual grid was placed over the sections and the quantitative detection of inflammation per visual field was carried out according to the following scheme: none (0), low (1), moderate (2), much (3).
Results and Discussion
Our plan of synthesis was based on our previous publications on metabolically stabilized NT(8-13) derivatives (Scheme 1) [7, 28, 29] In detail, we applied solid-phase methods with repetitive cycles of Fmoc deprotection with piperidine and acylation with the respective Fmoc-protected amino acids. Amino acid activation was done in the presence of PyBOP/HOBt, thus allowing us to incorporate t-leucine, tyrosine, proline, lysine, and amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid. The more powerful coupling agent HATU was employed for the attachment of N-(4-aminobutyl)-glycine, for the lysine linker as well as for the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), which was coupled as the commercially available tri-t-butyl ester derivative. Microwave acceleration proved to be advantageous for both Fmoc deprotection and acylation reactions. For a safe peptide cleavage without concomitant t-butylation of the peptide side chains, we decided to apply our recently published two step protocol removing the t-butyl-based protective groups by a pre-treatment with 10% sulfuric acid in dioxane at 8 °C at first [10] . Thereafter, final cleavage from the resin with TFA resulted in the formation of crude peptide with acceptable amounts of t-butylated byproduct, sufficiently pure to allow successful high-performance liquid chromatography (HPLC) purification. The biodistribution studies of [ 177 Lu]NT127 were carried out with HT29 tumor-bearing nude mice and showed a strong accumulation of the tracer in the kidney with 38 ± 1% ID/g at 1 h post-injection (p.i.), which was reduced to 20% ± 5% ID/g at 24 h p.i. (Figure 3 ). [
177 Lu]NT127 showed the second highest accumulation in the HT29 tumor at 1 h p.i. (1.5% ± 0.2% ID/g), whereas after 24 h the tracer was partially washed out again (0.6% ID/g). In the liver the radioactivity concentration was 0.7% ± 0.1% ID/g after 1 h and 0.4% ID/g after 24 h. The clearance from blood was very fast, resulting in 0.05% ID/g in blood at 1 h p.i. which was reduced to 0.01% ID/g at 24 h p.i., providing an excellently high tumor-to-blood ratio of 30 (60 min p.i.) and 60 (24 h p.i.), respectively. In all experiments, the course of the body weight of the treated animals during therapy did not reveal a static decrease, indicating the physical fitness of the animals ( Figure S3 ). However, a statistical analysis of the differences in body weight has not been performed due to the low number of animals used in this initial study. In group 1 that received two doses of 11-15 MBq and 17-23 MBq for each animal at day 0 and day 6, respectively, no change in tumor growth was observed when compared to the control group (Figure 4a ). The animals in treatment group 2, receiving four fractionated doses of 11-14 MBq/mouse at days 0, 3, 6 and 10, also did not show any significant change in the mean tumor growth (Figure 4b ). It is worth mentioning that two of the four treated mice of this group showed reduced tumor growth, however, the mean value over all four animals did not reveal any significant difference in the relative tumor growth. In contrast to the fractionated administration, the animals in treatment group 3 received a single high dose of 50 MBq per animal at the beginning of radiotherapy. These animals showed a significant reduction of about 50% in the mean tumor growth for all treated animals compared to the sham-treated controls (Figure 4c ). tumor region compared to the corresponding sham-treated animal, as shown in Figure 5 . However, we could not detect any significant changes in the tumor uptake of [ 68 Ga]DOTA-RGD between treated and untreated animal groups at later time points of more than seven days after treatment (Figure 4f ). This result might reflect the response of HT29 tumors toward radiation, resulting in regeneration of maximal integrin expression in the tumor region that did not differ significantly any more from the level that was found in sham-treated animals at day 7 and later after treatment. Noteworthy, HT29 are well-known to show a radiation-induced increase in radioresistance at low doses [41] , so this phenomenon could account for the weak response of HT29 tumors toward fractionated therapy by administration of four equal doses (group 3, Figure 4b ). Taken together, the single high-dose endoradiotherapy with 50 MBq [ 177 Lu]NT127 showed a substantial mean effect of 50% reduced tumor diameter, which is comparable to the result reported by Schubiger and coworkers for the rhenium-labeled peptide analog [24] . Moreover, preliminary µPET experiments identified day 7 after treatment as a potential time point for the analysis of integrin expression by RGD-PET, trying to identify an anti-angiogenic effect as an early predictor of response to endoradiotherapy with [ 177 Lu]NT127.
The clearance of [ 177 Lu]NT127 predominantly occurred through the kidney and to a lower portion through the liver (Figure 3 ), so that these organs received the highest radiation dose during tumor therapy. Therefore, we performed histological staining to study potential tissue damage, e.g., fibrotic lesions, in kidney and liver. In particular, both the glomeruli and the tubules in the kidney sections from animals that received a two-time consecutive dose show strong fibrosis compared to sham-treated control animals ( Figure 6 ). In the corresponding liver sections, both the singular and the sequential dose led to increased tissue damage ( Figure 6 ). This finding might hamper the translation of the NTS1-mediated radiotherapy approach with [
177 Lu]NT127 into human application in the future. In medical oncology, it is desirable to predict as early as possible whether an individual tumor responds to treatment. Structural imaging techniques such as X-ray computerized tomography (CT) or magnetic resonance imaging (MRI) capitalize on changes in tumor size for this purpose. However, a treatment-induced decrease of tumor size does often not occur until weeks to months after institution of treatment; furthermore, e.g., in lymphomas, non-neoplastic scar tissue may persist despite eradication of the tumor cells, leading to false-negative CT or MRI results. Therefore, the possible value of the molecular imaging modality PET for this purpose has been subject of considerable research efforts in the last decade (for a review, see [42] ). The PET measurement of glucose consumption using [ 18 F]fluorodeoxyglucose has, indeed, been proven to be of some value in this regard and, in particular, for establishing proof of treatment response in lymphomas, colorectal carcinomas, and gastrointestinal stroma tumors.
Changes in tumor vasculature are thought to have an important role in determining tumor response to radiotherapy [43] . Furthermore, radiation treatment does not only destroy the neoplastic cells, but also the vascular bed of the tumor as endothelial cells are even more sensitive to radiation than most cancer cells. Therefore, in this study, in addition to tumor volume, we analysed integrin expression to predict treatment effect. In the single-dose group that responded by significant tumor shrinkage to therapy radioreceptor treatment produced also an early decrease in RGD tracer uptake as measured by PET. However, this was only short-lived, although the treated animals consistently had lower tumor volumes than those in the control group until the end-point of treatment at day 28. One possible explanation for this phenomenon is provided by inflammatory changes occurring after initial radiation damage to the vascular bed of the tumors and to the tumor cells themselves. Indeed, some evidence for that could be seen in our histopathological specimens. To date, literature is scarce with regard to alterations of integrin tissue expression caused by radiation treatment. Therefore, this interpretation of our results must remain speculative, awaiting confirmation by future research.
Conclusions
With [
177 Lu]NT127 in our hands, we offer an agonist radiopeptide with high-affinity to NTS1, providing the option to study endoradiotherapy with that radiopeptide in preclinical animal models. In NTS1-positive HT29-tumor-bearing nude mice, we observed decreased tumor progression after administration of a single high-dose of the radiopeptide. In the sequentially treated animals, the decreased tumor progression was less pronounced visible when analyzing the tumor diameter. However, our preliminary PET imaging data at day 7 after treatment with a single high dose of 
